A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin ineligible muscle invasive bladder cancer
Meeting Abstract
Satkunasivam, R.; Teh, B. S.; Riveros, C.; Lim, K.; Wallis, C. J. D.; Hu, S.; Melchiode, Z.; Nikolos, F.; Miles, B. J.; Kaushik, D.; Chen, S. H.; Efstathiou, E.; Chan, K. S.; Esnaola, N. F.; Sonpavde, G. P.